Malarone

See also: Generic Malarone Pediatric

Malarone is a brand name of atovaquone/proguanil, approved by the FDA in the following formulation(s):

MALARONE (atovaquone; proguanil hydrochloride - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: July 14, 2000
  
  Strength(s): 250MG;100MG ^[RLD][AB]

Has a generic version of Malarone been approved?

A generic version of Malarone has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Malarone and have been approved by the FDA:

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE (atovaquone; proguanil hydrochloride tablet; oral)

• 
  Manufacturer: GLENMARK GENERICS
  
  Approval date: January 12, 2011
  
  Strength(s): 250MG;100MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Malarone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Combination of atovaquone with proguanil for the treatment of protozoal infections
  Patent 5,998,449
  Issued: December 7, 1999
  Inventor(s): Gutteridge; Winston Edward & Hutchinson; David Brian Ashton & Latter; Victoria Susan & Pudney; Mary
  Assignee(s): Glaxo Wellcome Inc.
  The invention relates to combinations of atovaquone and proguanil, their use in the treatment and propinylaxis of parasitic infections, such as protozoal parasitic infections, e.g. malaria and toxoplasmosis, and infections caused by P.carinii and their use in the manunfacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
  
  Patent expiration dates:
  
  
  • November 25, 2013
    
    ✓ 
    Patent use: TREATMENT OF PROTOZOAL INFECTION
  
  
  
  • May 25, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Combination of atovaquone with proguanil for the treatment of protozoal infections
  Patent 6,166,046
  Issued: December 26, 2000
  Inventor(s): Gutteridge; Winston Edward & Hutchinson; David Brian Ashton & Latter; Victoria Susan & Pudney; Mary
  Assignee(s): Glaxo Wellcome Inc.
  The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
  
  Patent expiration dates:
  
  
  • November 25, 2013
    
    ✓ 
    Patent use: METHOD OF USE OF ATOVAQUONE AND PROGUANIL
  
  
  
  • May 25, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Preventing protozoal infections
  Patent 6,291,488
  Issued: September 18, 2001
  Inventor(s): Gutteridge; Winston Edward & Hutchinson; David Brian Ashton & Latter; Victoria Susan & Pudney; Mary
  Assignee(s): Glaxo Wellcome Inc.
  The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
  
  Patent expiration dates:
  
  
  • November 25, 2013
    
    ✓ 
    Patent use: METHOD OF USE OF ATOVAQUONE AND PROGUANIL
  
  
  
  • May 25, 2014
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Malarone Consumer Information (Drugs.com)
• Malarone Consumer Information (Wolters Kluwer)
• Malarone Consumer Information (Cerner Multum)
• Malarone Advanced Consumer Information (Micromedex)
• Atovaquone/Proguanil Consumer Information (Wolters Kluwer)
• Atovaquone and proguanil Consumer Information (Cerner Multum)
• Atovaquone and chloroguanide Advanced Consumer Information (Micromedex)
• Atovaquone and proguanil Advanced Consumer Information (Micromedex)
• Atovaquone and Proguanil Hydrochloride AHFS DI Monographs (ASHP)